Predictive role of interphase cytogenetics for survival of patients with multiple myeloma

Journal of Clinical Oncology

Volumn 18, Issue 4, 2000, Pages 804-812

  Königsberg, Robert ^a   Zojer, Niklas ^a   Ackerman, Jutta ^a   Krömer, Elisabeth ^a   Kittler, Harald ^a   Fritz, Elke ^a   Kaufmann, Hannes ^a   Nösslinger, Thomas ^a   Riedl, Lucia ^a   Gisslinger, Heinz ^a   Jäger, Ulrich ^a   Simonitsch, Ingrid ^a   Heinz, Renate ^a   Ludwig, Heinz ^a   Huber, Heinz ^a   Drach, Johannes ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 14Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHROMOSOME DELETION 13; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 14; CONTROLLED STUDY; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTERPHASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

EID: 0343049149     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.4.804     Document Type: Article

References (35)

1. Bataille R, Harousseau JL: Multiple myeloma. N Engl J Med 336:1657-1664, 1997
2. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91-97, 1996
3. Barlogie B, Jagannath S, Desikan KR, et al: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93:55-65, 1999
4. Durie BG, Salmon SE: A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842-845, 1975
5. Greipp PR, Lust JA, O'Fallon WM, et al: Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 81:3382-3387, 1993
6. San Miguel J, Garcia-Sanz R, Gonzalez M, et al: A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 85:448-455, 1995
7. Greipp PR, Raymond NM, Kyle RA, et al: Multiple myeloma: Significance of plasmablastic subtype in morphological classification. Blood 65:305-310, 1985
8. Bartl R, Frisch B, Burkhardt R, et al: Bone marrow histology in myeloma: Its importance in diagnosis, prognosis, classification and staging. Br J Haematol 51:361-375, 1982
9. Fritz E, Ludwig H, Kundi M: Prognostic relevance of cellular morphology in multiple myeloma. Blood 63:1072-1079, 1984
10. Cuzick J, Cooper EH, Maclennan IC: The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis. Br J Cancer 52:1-6, 1985
11. Bataille R, Boccadoro M, Klein B, et al: C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood 80:733-737, 1992
12. Dimopoulos MA, Barlogie B, Smith TL, et al: High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. Ann Intern Med 115:931-935, 1991
13. Kyle RA: Why better prognostic factors for multiple myeloma are needed. Blood 83:1713-1716, 1994 (editorial)
14. Tricot G, Barlogie B, Jagannath S, et al: Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250-4256, 1995
15. Tricot G, Sawyer JR, Jagannath S, et al: Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. J Clin Oncol 15:2659-2666, 1997
16. Weh HJ, Gutensohn K, Selbach J, et al: Karyotype in multiple myeloma and plasma cell leukaemia. Eur J Cancer 29A:1269-1273, 1993
17. Lai JL, Zandecki M, Mary JY, et al: Improved cytogenetics in multiple myeloma: A study of 151 patients including 117 patients at diagnosis. Blood 85:2490-2497, 1995
18. Drach J, Schuster J, Nowotny H, et al: Multiple myeloma: High incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization. Cancer Res 55:3854-3859, 1995
19. Flactif M, Zandecki M, Lai JL, et al: Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma. Leukemia 9:2109-2114, 1995
20. Tabernero D, San Miguel J, Garcia-Sanz M, et al: Incidence of chromosome numerical changes in multiple myeloma: Fluorescence in situ hybridization analysis using 15 chromosome-specific probes. Am J Pathol 149:153-161, 1996
21. Zandecki M, Lai JL, Facon T: Multiple myeloma: Almost all patients are cytogenetically abnormal. Br J Haematol 94:217-227, 1996
22. Perez-Simon JA, Garcia-Sanz R, Tabernero MD, et al: Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. Blood 91:3366-3371, 1998
23. Zojer N, Königsberg R, Ackermann J, et al: In multiple myeloma, deletion of 13q14 remains an independent adverse prognostic parameter despite its frequent detection by interphase FISH. Blood (in press)
24. Drach J, Ackermann J, Fritz E, et al: Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 92:802-809, 1998
25. Blade J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 102:1115-1123, 1998
26. Avet-Loiseau H, Garand R, Gaillard F, et al: Detection of t(11;14) using interphase molecular cytogenetics in mantle cell lymphoma and atypical chronic lymphocytic leukemia. Genes Chromosomes Cancer 23:175-182, 1998
27. Drach J, Angerler J, Schuster J, et al: Interphase fluorescence in situ hybridization identifies chromosomal abnormalities in plasma cells from patients with monoclonal gammopathy of undetermined significance. Blood 86:3915-3921, 1995
28. Bartl R, Frisch B, Fateh-Moghadam A, et al: Histologic classification and staging of multiple myeloma: A retrospective and prospective study of 674 cases. Am J Clin Pathol 87:342-355, 1987
29. Cigudosa JC, Rao PH, Calasanz MJ, et al: Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood 91:3007-3010, 1998
30. Rao PH, Cigudosa JC, Ning Y, et al: Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood 92:1743-1748, 1998
31. Sawyer JR, Lukacs JL, Munshi N, et al: Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood 92:4269-4278, 1998
32. Shaughnessy J, Tian E, Bell T, et al: Molecular cytogenetic analysis of chromosome 13q14, site of a putative tumor suppressor gene in multiple myeloma (tsg-mm). Blood 92:259a, 1998 (suppl 1, abstr)
33. Liu Y, Hermanson M, Grander D, et al: 13q deletions in lymphoid malignancies. Blood 86:1911-1915, 1995
34. Bullrich F, Veronese ML, Kitada S, et al: Minimal region of loss at 13q14 in B-cell chronic lymphocytic leukemia. Blood 88:3109-3115, 1996
35. Döhner H, Stilgenbauer S, James MR, et al: 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood 89:2516-2522, 1997